Dr. Dolan has ongoing collaborations with Dr. Celalettin Ustun in the Division of Hematology, Oncology and Transplantation exploring the impact of cytogenetic findings on hematopoietic stem cell transplant outcomes. These projects have investigated the role of classical (G-banding) and molecular cytogenetics (fluorescence in situ hybridization, FISH) in assessing the level of disease burden before bone marrow or stem cell transplantation.In another collaboration with Drs. Ustun, Michael Linden (Laboratory Medicine and Pathology) and others in the United States and internationally, Dolan is exploring the role of mast cells in core-binding factor acute myeloid leukemias. Dolan is also working with Dr. Ustun and Drs. Linden, Sophia Yohe and Elizabeth Courville (Laboratory Medicine and Pathology) on a project to determine if residual disease at the time of transplant, as assessed by cytogenetic and other methods, impacts outcomes of various types of pre-transplant conditioning regimens.Dolan is also collaborating with Dr. Aleksandr Lazaryan and colleagues in the Division of Hematology, Oncology and Transplantation in a study to determine the prognostic significance of cytogenetic abnormalities in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission.Dolan is a co-investigator with Dr. Ioannis Koutlas and others in the Department of Oral Pathology in studies designed to determine whether the PLAG1 gene is rearranged in entities other than pleomorphic adenomas arising in salivary glands. She is also working with a colleague at Vanderbilt University on an immunohistochemical and FISH study of Ewing sarcoma and atypical teratoid/rhabdoid tumors.
